Cadrenal Therapeutics Expands the Scope of Tecarfarin to Incorporate Patients With Implanted Medical Devices for Heart Diseases
Wednesday, August 02, 2023
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company, has recently announced its plan to expand the focus of its late-stage novel oral anticoagulant, tecarfarin. The objective is to cater to patients with implanted medical devices for heart diseases who currently lack effective anticoagulant treatment options.
According to the CEO of Cadrenal Therapeutics, Quang Pham, the company aims to advance tecarfarin in targeted indications where the existing Vitamin K antagonists, such as warfarin, have failed to provide reliable anticoagulation. For patients with implanted medical devices like left ventricular assist devices (LVADs), warfarin's metabolism poses challenges and results in suboptimal anticoagulation. In contrast, tecarfarin is designed to overcome warfarin's metabolism problem through an alternative pathway, offering a more dependable pharmacokinetic profile. The company is enthusiastic about expanding the focus of tecarfarin within this patient population
.
Based on Cadrenal's market research, it is estimated that around 12,000 patients in the U.S. with LVADs struggle to maintain stable anticoagulation with warfarin. Cadrenal believes this represents a significant addressable market opportunity of approximately U.S. $600 million per year. Notably, direct-acting oral anticoagulants like Eliquis and Xarelto are not currently prescribed for these specific patients.
The company's decision to explore this additional indication for tecarfarin is based on clinical data, market research, and insights from key industry experts. Cadrenal Therapeutics is committed to addressing the unmet needs of patients with implanted medical devices for heart diseases and is looking forward to potentially benefiting this underserved population with its innovative anticoagulant.
